FDA 483 - Bret R. Rutherford, M.D. - January 10, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
The New York State Psychiatric Institute received a Form 483 with three observations during an inspection from December 2022 to January 2023. The observations primarily concern failures in clinical trial conduct, including implementing changes without Institutional Review Board (IRB) approval, enrolling subjects who did not meet protocol criteria, and inadequate study monitoring. These issues indicate significant deviations from investigational plan requirements and proper oversight.
ID · 48d60673-b6e3-4572-b88f-b7b637329564